Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, double-blind, placebo-controlled, ascending-dose, clinical trial of intravenous microplasmin administration in patients with acute ischemic stroke

Next Previous
X
Search
Trial Profile

A multicentre, double-blind, placebo-controlled, ascending-dose, clinical trial of intravenous microplasmin administration in patients with acute ischemic stroke

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocriplasmin (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MITI-IV
  • Sponsors Oxurion; ThromboGenics

    • Most Recent Events

    • 01 Dec 2009 Results published in Stroke.
    • 29 Sep 2008 Results have been reported in a ThromboGenics media release.
    • 10 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top